To ascertain the possible involvement of the enhanced ICAM1 expression of the senescent cells in increasing the adhesion, we added decreasing dilutions of an anti-ICAM1 blocking antibody during the time course of the adhesion test: the antibody addition led to a progressive dose-dependent inhibition of the cancer cell adhesion (Fig. 6C), revealing that the ability of the cancer cells to better interact with senescent HPMCs is related to the increased expression of ICAM1 on the cell plasma membranes of the mesothelial cells, as reported [10], [24]. This evidence concerns the gene ICAM1 and cancer.